Van Creveldkliniek, University Medical Center Utrecht, Utrecht, the Netherlands.
Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, the Netherlands.
J Thromb Haemost. 2017 Sep;15(9):1788-1798. doi: 10.1111/jth.13778. Epub 2017 Aug 17.
Essentials Targeted treatment for hemophilic arthropathy, still causing significant morbidity, is lacking. This study evaluates the efficacy of a fusion of protein of interleukin(IL)-4 and IL-10. In vitro the fusion protein prevents blood-induced cartilage damage in a dose-dependent manner. In hemophilic mice, the IL4-10 fusion protein ameliorates cartilage damage upon joint bleeding.
Background Joint damage still causes significant morbidity in hemophilia. It results from synovial inflammation and direct cartilage-degenerating properties of blood components. Interleukin (IL)-4 and IL-10 have been shown to protect cartilage from blood-induced damage. Recently an IL4-10 fusion protein has been developed to combine the function of IL-4 and IL-10 and increase their bioavailability. Objectives In this study we evaluate whether this IL4-10 fusion protein protects against blood-induced joint damage. Methods In vitro, human cartilage explants were exposed to whole blood and simultaneously to a broad concentration range of the IL4-10 fusion protein. Effects on cartilage matrix turnover were compared with the individual cytokines. Moreover, the influence of the fusion protein and its individual components on IL-1β and IL-6 production was investigated. In hemophilia A mice, the effect of intra-articular treatment on synovitis and cartilage damage resulting from joint bleeding was evaluated by histochemistry. Results In vitro, the fusion protein prevented blood-induced cartilage damage in a dose-dependent manner, with equal effectiveness to the combination of the separate cytokines. In whole blood cultures 10 ng mL fusion protein completely blocked the production of IL-1β and IL-6 by monocytes/macrophages. In hemophilic mice, intra-articular injection of IL-4 and IL-10 did not influence synovitis or cartilage degeneration. In contrast, equimolar amounts of the fusion protein attenuated cartilage damage upon repeated joint bleeding, although synovial inflammation was hardly affected. Conclusions Overall, this study shows that the IL4-10 fusion protein prevents blood-induced cartilage damage in vitro and ameliorates cartilage degeneration upon joint bleeding in hemophilic mice.
针对仍然导致显著发病率的血友病性关节病,缺乏靶向治疗。本研究评估白细胞介素(IL)-4 和 IL-10 融合蛋白的疗效。体外,融合蛋白以剂量依赖的方式防止血液引起的软骨损伤。在血友病小鼠中,IL4-10 融合蛋白可改善关节出血后的软骨损伤。
背景:关节损伤仍然导致血友病患者发病率高。它是由滑膜炎症和血液成分的直接软骨退化特性引起的。白细胞介素(IL)-4 和 IL-10 已被证明可防止软骨受到血液损伤。最近开发了一种 IL4-10 融合蛋白,以结合 IL-4 和 IL-10 的功能并增加其生物利用度。目的:本研究评估这种 IL4-10 融合蛋白是否能防止血液引起的关节损伤。
在体外,人软骨外植体暴露于全血中,并同时暴露于广泛浓度范围内的 IL4-10 融合蛋白。将其对软骨基质周转的影响与单独的细胞因子进行比较。此外,还研究了融合蛋白及其各个成分对 IL-1β 和 IL-6 产生的影响。在血友病 A 小鼠中,通过组织化学评估关节内治疗对关节出血引起的滑膜炎和软骨损伤的影响。
在体外,融合蛋白以剂量依赖的方式防止血液引起的软骨损伤,其效果与单独细胞因子的组合相当。在全血培养物中,10ng/ml 的融合蛋白可完全阻断单核细胞/巨噬细胞产生的 IL-1β 和 IL-6。在血友病小鼠中,关节内注射 IL-4 和 IL-10 不影响滑膜炎或软骨退化。相反,等量的融合蛋白可减轻反复关节出血后的软骨损伤,尽管对滑膜炎症的影响很小。
总之,本研究表明,IL4-10 融合蛋白可防止体外血液引起的软骨损伤,并改善血友病小鼠关节出血后的软骨退化。